HDAC9 and cancer: Among these, HDAC inhibitors (cluster #4, Year = 2013) are representative regulatory drugs that indirectly induce histone acetylation by disrupting HDAC activity, leading to the re-expression of regulatory genes in cancer cells and reversing malignant phenotypes (46).